Biodexa Pharmaceuticals (BDRX) Registration Filing summary

Company overview and business model

• Acquisition-focused clinical-stage biopharmaceutical company developing products for diseases with unmet medical needs, including FAP, NMIBC, T1D, and rare/orphan brain cancers.

• Pipeline includes eRapa (licensed April 2024), tolimidone, and MTX110, each targeting specific disease pathways and delivery challenges.

• Proprietary drug delivery technologies: Q-Sphera (sustained delivery), MidaSolve (direct delivery), and MidaCore (targeted delivery), though no active R&D programs currently based on these platforms.

Financial performance and metrics

• As of December 31, 2023, cash and cash equivalents were £5.97 million, with total equity of £4.68 million.

• Pro forma as-adjusted for recent offerings, cash and cash equivalents would be £13.36 million and total equity £12.30 million.

• Recent offerings in July 2024 raised approximately $5.0 million in gross proceeds.

Use of proceeds and capital allocation

• No proceeds from the resale of shares by selling shareholders; proceeds from warrant exercises, if any, will be received by the company.

• Funds are intended to support business development and expansion; no dividends are planned in the foreseeable future.